m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00637)
Name
Ganciclovir
Synonyms
2'-NDG; 2'-Nor-2'-deoxyguanosine; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BIOLF-62; BW 759; BW 759U; BW-759U; BW-795; BW-B 759U; Biolf 62; Citovirax; Cymevan; Cymeven; Cymevene; Cymevene (TN); Cytovene; Cytovene (TN); Cytovene-IV; DRG-0018; G 2536; GA2; GANCICLOVIR SODIUM; GCV; GCV & 1110U81; GCV & MSL; Ganciclovir & C34-dgA immunotoxin; Ganciclovir & D5-dgA immunotoxin; Ganciclovir (JAN/USP/INN); Ganciclovir [USAN:INN:BAN:JAN]; Ganciclovirum; Ganciclovirum [Latin]; Gancyclovir; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-and MSL, neutralizing monoclonal antibody; HHEMG; Hydroxyacyclovir; IN1478; MB3795; RS-21592; ST-605; Virgan; Vitrasert; Vitrasert (TN); Zirgan
    Click to Show/Hide
Status
Approved
Structure
Formula
C9H13N5O4
InChI
1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
InChIKey
IRSCQMHQWWYFCW-UHFFFAOYSA-N
PubChem CID
135398740
VARIDT Drug ID
DR00027
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Ganciclovir. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Ganciclovir through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5). [1], [2]
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Ganciclovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ganciclovir through regulating the expression of Breast cancer resistance protein (ABCG2). [3], [4]
References
Ref 1 The m(6)A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21441-21449. doi: 10.1073/pnas.2000516117. Epub 2020 Aug 19.
Ref 2 Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64. doi: 10.2174/156800805774912953.
Ref 3 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 4 Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501. doi: 10.1007/s11626-010-9274-6. Epub 2010 Feb 5.